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We examined the possible involvement of vitamin D receptor (VDR) gene polymorphisms
in patients on maintenance hemodialysis and further investigated the relation between
VDR genotypes and bone histology.  Two hundred and nine patients undergoing regular
hemodialysis (male/female ratio, 124/85) were included in this study.  DNA was extracted
from peripheral blood leukocytes.  VDR genotypes were analyzed as restriction fragment
length polymorphisms, by using BsmI, ApaI, TaqI and FokI.  Lumbar bone mineral
density was measured by dual-energy X-ray absorptiometry, and expressed as a Z-
score.  Serum 1,25(OH)2D3, osteocalcin and intact-parathyroid hormone (i-PTH) were
determined by an immunoradiometric assay.  In 97 patients, bone biopsy was performed
and the histology was divided into osteitis fibrosa, mild lesion, adynamic bone disease
and osteomalacia.  Serum levels of osteocalcin, i-PTH and bone mineral density were
significantly lower in the presence of B, A, t and f alleles.  However, in this study, we did
not find any association between bone histology and the four VDR genotypes.  We
concluded that renal osteodystrophy in dialysis patients was modified by environmental
factors such as medication with active vitamin D, age, gender and duration of chronic
renal failure, and that the impact of the VDR allelic effect may play a small role in
determining on bone histology.
Key words:  bone mineral density; hemodialysis; renal osteodystrophy; vitamin D receptor gene
polymorphism
Abbreviations:  bp, base pair; BMD, bone mineral density; IGF, insulin-like growth factor; i-PTH, intact-
parathyroid hormone; kb, kilobase; nVDRE, negative vitamin D responsive element; RFLP, restriction
fragment length polymorphism; VDR, vitamin D receptor
Children obviously bear a striking likeness to
their parents, and bone density has been con-
sidered a genetic determinant in the inheritance
of appearance from parents to children.  Smith
and colleagues (1973) assessed bone density on
the midshaft radius in monozygotic twins and
dizygotic twins to prove for the first time that a
significantly larger variation in intrapair differ-
ences was observed in dizygotic twins compar-
ed to that in monozygotic twins.  Later investi-
gations based on twin studies and epidemio-
logic surveys all favored this finding, indicating
that there is an inheritable component related to
bone mass which may be associated with 50 to
80% of bone mass features in individuals.  How-
ever, the search for a gene which determines
bone mass has long been unsuccessful.
In 1994, Morrison and others (1992) de-
monstrated that common allelic polymorphisms
in the gene encoding the vitamin D receptor
(VDR) were significantly correlated with bone
density in healthy individuals.  Since then, a
considerable number of studies were reported to
confirm this interesting finding.  However, the
results have been controversial to date.
Recently, VDR has become a focus of re-
search interest not only as a candidate gene con-
trolling bone density, but also as a gene associ-
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ated with bone turnover.  Patients with chronic
renal failure are generally accompanied by
renal osteodystrophy caused by anomalies in
bone turnover.  Due to the successful spread of
maintenance hemodialysis, patients with
chronic renal failure have attained considerable
improvement in survival time, but at the same
time patients are increasingly left confronted
with renal osteodystrophy.  Thus, renal osteo-
dystrophy is an important factor influencing the
quality of life of patients on maintenance hemo-
dialysis.  To date, however, there have been a
few reports describing the relationship between
the prevalence of renal osteodystrophy and
VDR polymorphisms.  In the present study, we
assessed a possible correlation between VDR
polymorphisms and renal osteodystrophy in
patients undergoing maintenance hemodialysis
by measuring bone mineral density (BMD) and
markers for bone turnover.  We also assessed
such correlation in patients on maintenance
hemodialysis by performing a bone biopsy.
Materials and Methods
Patients
The subjects consisted of 209 patients (124
males and 85 females) with chronic renal fail-
ure on maintenance hemodialysis.  Primary dis-
eases included chronic glomerulonephritis,
diabetes mellitus, rheumatoid arthritis, auto-
somal dominant polycystic kidney disease and
other miscellaneous diseases in 123, 48, 12, 8
and 18 patients, respectively (Table 1).
Table 1.  Patient characteristics
Number of patients Age (year) Z-score
Chronic glomerulonephritis 123 (74/49) 55 ± 11* –0.105 ± 1.341
Diabetes mellitus   48 (30/18) 63 ± 11* 0.331 ± 1.042
Rheumatoid arthritis   12 (  2/10) 58 ±   9 –0.233 ± 0.681
Polycystic kidney disease     8 (  5/  3) 59 ± 19 0.167 ± 1.150
Others   18 (13/  5) 56 ± 24 –0.750 ± 1.666
Values are expressed as mean ± SD.
(  ), male/female ratio.
* P < 0.05; chronic glomerulonephritis versus diabetes mellitus.
RFLP analysis of VDR locus
Prior to trial, informed consent was individually
obtained from patients and their relatives by the
attending physicians following full explana-
tions of the aim of the research, and guarantees
of privacy.  Two-milliliter aliquots of periph-
eral blood samples were collected from the
patients and stored in the presence of EDTA.
Genomic DNA was extracted from leukocytes
obtained from the blood samples with the con-
ventional extraction method using phenol/
chloroform followed by ethanol precipitation.
So far, the VDR gene, mapped to the long
arm of human chromosome 12, was considered
to contain 9 exons.  In 1997, Miyamoto and co-
workers (1996, 1997) identified two previously
unreported exons located 20 kilobase (kb) up-
stream from the originally reported exon 1; sub-
sequently designated them exon 1A and exon
1B, and renamed exon 1 as exon 1C.  Thus, the
VDR gene is comprised of 11 exons which, to-
gether with intervening introns, span approxi-
mately 75 kb, where the translation start codon
is located in exon 2 as reported by Baker and
others (1998) (Fig. 1).  A restriction fragment
length polymorphism (RFLP) involving the loss
of an initiation codon (ATG) by a single base
substitution from T to C (ACG) starts transla-
tion from 9-base pair (bp) downstream, raising
the possibility that the polypeptides translated
from the two alleles differ by three amino acid
residues.
To amplify a 265-bp sequence in exon 2, a
10-µL reaction mixture containing 50 ng of
template DNA, 1 µmol/L each of the primers
VDR2a: 5'-AGCTGGCCCTGGCACTGA
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Exon   1A 1B       1C   2         3       4    5       6         7     8          9 
5' 3'  VDR gene
ATG                                                 
       
   TGA 
Fok I                                                       Bsm I    Apa I     Taq I   Taq I (invariant site)
UTR     3'
Exon 2                            Exon 7    Exon 8                                        Exon 9
5'
Chromosome 12
q                     p   
CTCTGCTCT-3' and VDR2b: 5'-ATGGAA
ACACCTTGCTTCTTC TCCCTC-3', 10-
mmol/L Tris-HCl (pH 8.3), 50-mmol/L KCl,
1.5-mmol/L MgCl2, 0.2 mmol/L each of deoxy-
ribonucleotide triphosphates and 0.25 U of Taq
DNA polymerase (Perkin-Elmer Co., Foster
City, CA) were incubated in a microtube using
a thermal cycler (Touch Down, Hybaid Ltd.,
Ashford, Middlesex, United Kingdom) (Gross
et al., 1996).  A reaction cycle consisting of
sequential incubations for denaturation at 94°C
for 45 s, for annealing at 60°C for 45 s, and for
extension at 72°C for 45 s was repeated 35
times, except that denaturation at 94°C for an
additional 7 min was included in the first cycle.
Five-microlitter aliquots of the polymerase
chain reaction (PCR) product was incubated at
37°C for 3 h in a 10-µL reaction mixture con-
taining 50-mmol/L NaCl, 10-mmol/L Tris-HCl
(pH 7.5), 10-mmol/L MgCl2, 1-mmol/L 1,4-di-
thiothreitol and 4 units of the restriction endo-
nuclease FokI (Nippon Gene, Toyama, Japan).
Aliquots of the FokI digest of PCR products
were electrophoresed for 30 min at 100 V through
a gel (1% agarose S plus 1% agarose X) con-
taining 0.4-µg/mL ethidium bromide prepared
in a buffer containing 89-mmol/L Tris-borate
and 2-mmol/L EDTA.  As DNA size markers,
φX174/HaeIII digest and φX174/Hinc-II digest
(Nippon Gene) were used.
DNA bands on the gel were visualized un-
der 312-nm UV lamp (ATTO Bioinstrument,
Tokyo, Japan) and fluorescent DNA bands were
photographed with a Polaroid camera for RFLP
assessment.  Upon digestion by FokI, the 165-
bp PCR products derived from an allele having
a FokI site in exon 2, designated f, were split
into two bands, 69 bp and 196 bp, respectively,
while those derived from an allele not having a
FokI site in the corresponding sequence, des-
ignated F, remained as a single band.  Thus,
genotypes of the PCR products derived from in-
dividual subjects were presented as ff, Ff or FF.
Genotyping was similarly performed re-
garding RFLPs involving BsmI and ApaI sites
in intron 8, and RFLP involving the TaqI site in
exon 9 (Tokita et al., 1996), using PCR primers
described by Morrison and others (1992).  The
825-bp PCR products derived from an allele
having a BsmI site in intron 8, designated b,
were split into two bands, 650 bp and 175 bp,
respectively, upon digestion with BsmI, while
those derived from an allele not having a BsmI
site in the corresponding sequence, designated
B, remained a single band.
The 740-bp PCR products derived from an
allele having both an ApaI and a TaqI site be-
tween intron 8 and exon 9, designated a, were
split into two bands, 529 bp and 211 bp, respec-
tively, upon digestion with ApaI, while those
Fig. 1.  Genomic organization and restriction map of the vitamin D receptor (VDR) gene.
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derived from an allele not hav-
ing an ApaI site in the corre-
sponding sequence, designated
A, remained a single band.
In exon 9, there is an addi-
tional invariant TaqI site that is
not involved in generating
RFLP.  Thus, the above 740-bp
PCR products derived from an
allele having an RFLP-associ-
ated TaqI site in exon 9, desig-
nated t, were split into three
bands, 291 bp, 247 bp and 202
bp, respectively, upon diges-
tion with TaqI, while those de-
rived from an allele not having
an RFLP-associated TaqI site in
the corresponding sequence,
designated T, were split into
two bands, 493 bp and 247 bp,
respectively (Fig. 2).
Measurements of bone
turnover markers and BMD
Serum 1,25(OH)2D3, osteo-
calcin and intact-parathyroid
hormone (i-PTH) were determined as bone
turnover markers.  Patients with fracture, scoli-
osis or lumbar osteoarthritis upon X-ray
examination were excluded from evaluation of
BMD, since bones with these anomalies could
provide abnormal BMD values.  BMD at the
lumbar spine (L2–L4) was measured by dual-
energy X-ray absorptiometry (model XR-26,
Norland, Fort Atkinson, WI).  For age- and
gender-matched comparisons, BMD values
were expressed as Z-scores.
Bone biopsy
Bone biopsy was performed in 97 patients with
chronic renal failure on maintenance hemo-
dialysis.  To determine the mineralization rate,
bones were subjected to tetracycline double-
labeling: tetracycline hydrochloride was given
at a dose of 750 mg/24 h for 2 days, and after a
cessation for the following 10 days, the drug
was further given during the next 4 days.  Bone
biopsy was performed within 7 days after ad-
ministration of the second label.  Before bone
biopsy was performed, diazepam and ketamine
were given.  Under local anesthesia with lido-
caine, bone specimens were taken vertically
from the right iliac crest with a manually driven
drill attached to Kitasato’s trephine.  During
this biopsy procedure, no patients complained
of severe pain.  None of the serious complica-
tions were experienced.  Biopsy specimens
were fixed in dehydrated ethanol, embedded in
methylmethacrylate and left for 7 days for com-
plete solidification.  Sections (4–5 µm) were cut
on a microtome, mounted on glass slides and
stained with Villanueva-Goldner and aluminon.
The bone turnover rate was quantitatively as-
sessed by bone histomorphometry.  According
to the classification described by Sherrard and
others (1993), bone tissues were histopatho-
logically diagnosed as osteitis fibrosa, osteo-
malacia and mild lesion and adynamic bone
disease (Table 2).
Fig. 2.  Restriction fragment length plymorphism analysis of poly-
morphic vitamin D receptor (VDR) alleles.  bp, base pair.
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Table 2.  Histologic classification of renal osteodystrophy
Area of osteoid Area of fibrosis Bone formation rate
(%) (%) (µm2/mm2 of tissue area/day)
Osteitis fibrosa < 15 > 0.5 Increased
Osteomalacia > 15 < 0.5 Decreased
Mixed* > 15 > 0.5 Normal
Mild lesion < 15 < 0.5 Normal (> 108)
Adynamic bone disease < 15 < 0.5 Decreased (< 108)
Area of osteoid, osteoid volume/bone volume; area of fibrosis, fibrosis volume/tissue volume; bone forma-
tion rate, bone formation rate/bone surface.
* Mixture of osteitis fibrosa and osteomalacia.
The table is cited from Sherrard et al. (1993).
Table 3.  Relationship between bone turnover markers and Bsm I genotypes of VDR
Genotype P*
    BB     Bb bb
Number of subjects     2 (1.0%)   38 (18.2%) 169 (80.9%)
Age (year)   77.5  ± 2.1   56.0 ± 15.8   57.0 ± 13.9 NS
Ca (mg/dL)     6.1  ± 3.3     7.4  ±  2.1     7.8  ±  2.2 NS
P (mg/dL)     6.5  ± 1.6     5.6  ±  2.0     5.7  ±  1.6 NS
Alkaline phosphatase (IU/L) 158 ± 102 149   ±  96 186  ± 307 NS
1,25 (OH)2D3 (pg/mL)     6.9  ± 5.7     8.9  ±  5.8     8.0  ±  5.6 NS
Osteocalcin (mg/dL)   43.5  ± 3.5   54.9 ± 30.6   78.0 ± 66.4 < 0.05
i-PTH (pg/mL) 130  ±  55 149  ± 144 278  ± 260 < 0.05
Z-score   –2.50 ±0.14   –0.50 ± 1.44     0.43 ± 1.58 < 0.01
* Significant difference in P values among the three genotypes.
i-PTH, intact parathyroid hormone; NS, not significant; VDR, vitamin D receptor.
Statistical analysis
The results were assessed by the analysis of
variance, contingency table test and regression
analysis.  P values < 0.05 were regarded as sig-
nificant.
Results
Regarding patient characteristics (Table 1),
average age and BMD values did not signifi-
cantly differ among patients with regard to pri-
mary diseases, except that the average age was
approximately 8 years older in the diabetes
mellitus group than in the chronic glomerulo-
nephritis group.
Allele and genotype frequencies for BsmI-
RFLP were 1.0%, 18.2% and 80.9% for BB, Bb
and bb, respectively (Table 3).  Compared to the
value of approximately 20% reported for BB in
the study of a sample of European population
(Uitterlinden et al., 1996), the present value of
1.0% was significantly lower, suggesting an
ethnic variation in allele frequencies.  The
above allele frequencies for the BsmI-RFLP did
not significantly differ among patients of dif-
ferent ages, or among those showing different
serum values for Ca, P, alkaline phosphatase or
active vitamin D.  Values for serum osteocalcin
were 43.5 ± 3.5 mg/dL, 54.9 ± 30.6 mg/dL and
78.0 ± 66.4 mg/dL for BB, Bb and bb, respec-
tively, indicating that the values in individuals
possessing the b haplotype were significantly
higher (P < 0.05).  Individuals possessing the b
haplotype also showed significantly higher
values for i-PTH: 130 ± 55 pg/mL, 149 ± 144
pg/mL and 278 ± 260 pg/mL for BB, Bb and bb,
respectively (P < 0.05).  The age- and gender-
matched Z-scores for BMD were also signifi-
cantly higher in individuals possessing b haplo-
type (P < 0.01):  –2.50 ± 0.14, –0.50 ± 1.44 and
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0.43 ± 1.58 for BB, Bb and bb, respectively.
Regarding ApaI-RFLP, allele and genotype
frequencies were 11.0%, 37.8% and 51.2% for
AA, Aa and aa, respectively (Table 4).  Again,
Table 6.  Relationship between bone turnover markers and FokI-genotypes of VDR
Genotype P*
   FF     Ff ff
Number of subjects   82 (39.2%)   93 (44.5%)   34 (16.3%)
Age (year)   58.3 ± 14.8   56.4 ± 14.5   56.5 ± 13.2 NS
Ca (mg/dL)     8.4  ±  2.1     7.4  ±  2.3     7.4  ±  2.2 NS
P (mg/dL)     5.6  ±  1.6     5.8  ±  1.6     5.7  ±  1.7 NS
Alkaline phosphatase (IU/L) 179  ± 257 197  ± 344 131  ±   84 NS
1,25 (OH)2D3 (pg/mL)     9.1  ±  6.4     6.7  ±  3.0     8.4  ±  6.7 NS
Osteocalcin (mg/dL)   80.8 ± 52.3   75.7  ±74.3   49.2 ± 34.5 < 0.05
i-PTH (pg/mL) 278  ± 236 260  ± 214 172  ± 112 NS
Z-score     0.40 ± 1.60     0.29 ± 1.66   –0.37 ± 1.42 < 0.05
* Significant difference in P values among the three genotypes.
i-PTH, intact parathyroid hormone; NS, not significant; VDR, vitamin D receptor.
Table 4.  Relationship between bone turnover markers and Apa I genotypes of VDR
Genotype P*
   AA     Aa aa
Number of subjects   23 (11.0%)   79 (37.8%) 107 (51.2%)
Age (year)   55.9 ± 16.7   56.7 ± 14.5   57.7 ± 13.0 NS
Ca (mg/dL)     7.4  ±  2.2     7.3  ±  2.2     8.1  ±  2.2 NS
P (mg/dL)     5.7  ±  2.0     5.8  ±  1.7     5.6  ±  1.5 NS
Alkaline phosphatase (IU/L) 164  ± 120 194  ± 375 170  ± 217 NS
1,25 (OH)2D3 (pg/mL)     6.1  ±  1.6   10.6  ±  7.3     6.7  ±  3.8 NS
Osteocalcin (mg/dL)   56.5 ± 30.0   65.4 ± 60.4   82.9 ± 58.7 NS
i-PTH (pg/mL) 129  ± 118 262  ± 207 273  ± 258 < 0.05
Z-score   –0.68 ± 1.50     0.32 ± 1.73     0.36 ± 1.50 < 0.05
* Significant difference in P values among the three genotypes.
i-PTH, intact parathyroid hormone; NS, not significant; VDR, vitamin D receptor.
Table 5.  Relationship between bone turnover markers and Taq I genotypes of VDR
Genotype P*
   TT     Tt tt
Number of subjects 169 (80.9%)   35 (16.7%)     5 (2.4%)
Age (year)   57.7 ± 13.6   54.3 ± 17.0   57.4 ± 19.8 NS
Ca (mg/dL)     7.9  ±  2.2     7.3  ±  2.4     6.7  ±  2.5 NS
P (mg/dL)     5.8  ±  1.6     5.5  ±  1.9     5.5  ±  1.8 NS
Alkaline phosphatase (IU/L) 185  ± 309 144  ± 103 201   ±  87 NS
1,25 (OH)2D3 (pg/mL)     7.5  ±  4.5   11.0  ±  8.6     6.2  ±  0.6 NS
Osteocalcin (mg/dL)   77.1 ± 66.0   58.3 ± 37.1   55.4 ± 26.9 NS
i-PTH (pg/mL) 273   ±  98 182  ± 172 129  ± 123 < 0.05
Z-score     0.45 ± 1.58   –0.56 ± 1.39   –1.55 ± 1.58 < 0.01
* Significant difference in P values among the three genotypes.
i-PTH, intact parathyroid hormone; NS, not significant; VDR, vitamin D receptor.
the frequencies differed from those reported in
the European population, but less significantly
than in cases of BsmI-RFLP.  Allele frequencies
for ApaI-RFLP did not significantly differ among
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patients of different ages, or among those show-
ing different serum values for Ca, P, alkaline
phosphatase, 1,25(OH)2D3 or osteocalcin.  How-
ever, values for i-PTH and Z-scores represent-
ing BMD were significantly higher in individ-
uals possessing the a haplotype.
Allele and genotype frequencies for TaqI-
RFLP were 80.9%, 16.7% and 2.4% for TT, Tt
and tt, respectively (Table 5), indicating that
genotype frequency for tt was extremely low.
Z-scores for BMD significantly varied among
patients having different genotypes; that is, the
highest score was obtained for TT, followed by
those for Tt and tt in that order.
Allele and genotype frequencies for the
FokI-RFLP were 39.2%, 44.5% and 16.3% for
FF, Ff and ff, respectively (Table 6).  Values for
osteocalcin and Z-scores significantly varied
among patients having different genotypes; i.e.,
the highest value was obtained for FF, followed
by those for Ff and ff in that order.
It is noted that allele and genotype frequen-
cies for RFLPs obtained with chronic renal
failure in the present study did not differ from
those reported for healthy subjects.
Distribution of serum osteocalcin levels
were presented with respect to genotyping for
Fig. 4.  Serum intact-parathyroid hormone (i-PTH)
levels compared among polymorphic vitamin D
receptor ( VDR) genotypes.  Values shown are mean
± SE.  [  ], number of subjects.
Fig. 3.  Serum osteocalcin levels compared among
polymorphic vitamin D receptor (VDR) genotypes.
Values shown are mean ± SE.  [  ], number of
subjects.
Fig. 5.  Z-scores compared among polymorphic
vitamin D receptor (VDR) genotypes.  Values shown
are mean ± SE.  [  ], number of subjects.
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BsmI, ApaI, TaqI and FokI RFLPs (Fig. 3).
Distribution of serum i-PTH levels (Fig. 4) and
Z-scores (Fig. 5) were similarly presented.
Low levels of osteocalcin and i-PTH were nota-
bly correlated with B, A, t and f  haplotypes,
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suggesting that VDR polymorphisms are cor-
related with BMD via bone turnover markers.
Histopathological diagnosis of bone biopsy
specimens revealed osteitis fibrosa, mild lesion,
adynamic bone disease and osteomalacia in 19,
57, 20 and 1 cases, respectively.  Distribution of
the incidences of these bone diseases among
RFLP genotypes did not differ by the restriction
endonuclease used:  in incidence, mild lesion
was the highest, osteitis fibrosa and adynamic
bone disease were almost equal, and osteomala-
cia was the lowest in all studies.  For example,
in BsmI-RFLP, 17 osteitides fibrosa, 47 mild
lesions, 15 adynamic bone diseases and 1 osteo-
malacia were found among patients having
genotype bb, and 1 osteitis fibrosa, 10 mild le-
sions and 5 adynamic bone diseases in those
having genotype Bb.  These constant distribu-
tion patterns of bone diseases among RFLPs
generated by different restriction endonucleases
were consistently demonstrated by the contin-
gency table analysis (Fig. 6).
With respect to a possible correlation be-
tween serum levels of bone turnover markers
and histologic types of bone diseases, both
osteocalcin and i-PTH levels were the highest
in osteitis fibrosa, followed by mild lesion, and
the values were lowest in adynamic bone dis-
ease.  There was a positive correlation between
osteocalcin and i-PTH, indicating that these two
markers were both useful in predicting renal
osteodystrophy (Fig. 7).
Fig. 6.  Histologic comparison of bone biopsy in terms of polymorphic vitamin D receptor (VDR) genotypes.
ADB, adynamic bone disease; ML, mild lesion; OF, osteitis fibrosa; OM, osteomalacia; RFLP, restriction
fragment length polymorphism.
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Fig. 7.  Serum levels of bone turnover markers
evaluated with respect to the histology of bone
biopsy.
Discussion
In the present study, a significant correlation
was demonstrated between patients with chron-
ic renal failure having the RFLP haplotypes B,
A, t and f and patients showing lower Z-scores
for BMD.  This fact suggests that particular
RFLP haplotypes can be used as a risk factor
predictive of osteoporosis.  Indeed, RFLP
haplotypes B, A, t and f were associated with
low levels of serum osteocalcin and i-PTH;
polymorphic VDR genes could determine dy-
namic features of bone remodeling via actions
of these bone turnover markers.
Carling and colleagues (1997) assessed
extracellular Ca2+-mediated suppression of i-
PTH secretion in 62 patients with primary
hyperparathyroidism due to parathyroid adeno-
ma using dispersed adenoma cells in vitro, and
showed that Ca2+-mediated PTH inhibition pro-
duced a higher median effective dose and re-
duced suppression in adenoma cells from pa-
tients who were homozygous for b, a and T
alleles.  These findings were consistent with the
positive correlation observed between particu-
lar VDR polymorphic alleles and serum i-PTH
in patients with chronic renal failure in the
present study.  There is a negative vitamin D
responsive element (nVDRE) on the PTH gene
to which 1,25(OH)2D3 acts negatively by bind-
ing to the nVDRE (Demay et al., 1992).  Taken
together, it seems that VDR polymorphisms
affect nVDRE-mediated regulation of the PTH
gene expression.
Vitamin D and PTH primarily act on osteo-
blasts by binding to respective cellular receptors.
Subsequently, the activated osteoblasts stimu-
late bone resorption through the monocyte-
macrophage colony-stimulating factor and the
osteoclast differentiation factor.  At the same
time, however, vitamin D stimulates normal
calcification of bone matrix including type I
collagen, alkaline phosphatase and osteocalcin
produced by osteoblasts.  PTH also enhances
calcification by stimulating the release of
insulin-like growth factor (IGF)-I and -II from
osteoblast cells, and stimulates the accumula-
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tion of IGF-I and transforming growth factor-β
in the bone.  Thus, PTH seems to be one of the
potent regulators of dynamic bone remodeling
(Christakos et al., 1989; Linkhart et al., 1989),
and VDR polymorphism may be associated
with the mechanism of bone remodeling.
Since a reduction in BMD is due to a failure
in normal bone remodeling, a VDR polymor-
phism could be associated with BMD at the
level of the bone remodeling process.
There remains the important question of
how BsmI- and ApaI-RFLPs, due to a nucleo-
tide change in introns, and TaqI-RFLP, due to a
synonymous codon change (ATC/ATT) in exon
9, lead to a functional change in VDR proteins.
Although an answer to the question of the
involvement of changes in 3'UTR, poly(A) tail,
transcription efficiency and messenger RNA
stability has been proposed  (Gross et al., 1998),
there has been no conclusive evidence which
can explain this problem.
Regarding FokI-RFLP, the nucleotide
change in the VDR gene was reported to alter
not only the translation initiation site but also
transcription efficiency as demonstrated by
luciferase assay, and change the translation effi-
ciency determined in vitro (Arai et al., 1997).
These changes should all affect BMD.
As Sainz and coworkers (1997) clearly dem-
onstrated, VDR gene polymorphisms and bone
density were significantly correlated with each
other in 100 prepubertal American girls of
Mexican descent in California.  The success of
their findings may be due to the recruitment of
females at puberty when bone density reaches
the maximum; during the puberty, genetic fac-
tors may most predominantly affect bone densi-
ty control, while environmental factors such as
nutrition and exercise may play more influential
roles at later ages (Cooper et al., 1996).
Histopathological diagnosis of bone biopsy
revealed osteitis fibrosa, mild lesion, adynamic
bone disease and osteomalacia in 19, 57, 20 and
1 cases, respectively.  The incidence distribu-
tion of these bone diseases did not vary when
different restriction endonucleases were used
for VDR genotyping.  A cyclical process, called
remodeling, maintains a dynamic steady state
of bone structure density without changing the
size and shape, through sequential resorption
and formation of a small amount of bone at the
same site.  Renal osteodystrophy can be defined
as a failure of normal bone remodeling (Hruska,
1997).  Upon the introduction of hemodialysis,
patients with end stage renal failure tend to have
complications with hyperphosphatemia, hypo-
calcemia, acidosis and a moderate increase in i-
PTH due to the retarded elimination of serum
phosphates and impaired activation of vitamin
D.  These signs are mainly associated with mild
lesion.  Complication with severe secondary
hyperthyroidism is associated with osteitis fi-
brosa.  When patients are medicated with calci-
um carbonate as a precipitant for aluminum ac-
cumulation or for hypocalcemia, or have com-
plications with diabetes mellitus, adynamic bone
disease develops.  In the case of 1,25(OH)2D3
deficiency and hypocalcemia, osteomalacia
develops due to insufficient calcification.  A
spectrum of bone diseases developing into renal
osteodystrophy may be partly influenced by
various factors including duration of chronic
renal failure, primary disease, age, complica-
tions, nutrition, extent of exercise, aluminum
accumulation and effectiveness of medication.
In the present study, although the pathogenesis
of renal osteodystrophy may well be affected by
VDR polymorphism at the stage of i-PTH
secretion and activation of osteoblasts associ-
ated with remodeling, the incidence distribution
of bone diseases did not vary depending on dif-
ferent restriction endonucleases used for VDR
genotyping.  This discrepancy may be explain-
ed by assuming that the haplotype-dependent
genetic consequences may have been obscured
by the prominent improvement of bone disease
induced by medication with active vitamin D
and calcium pharmaceuticals.
Bone turnover markers such as i-PTH and
osteocalcin have proven useful in predicting
renal osteodystrophy.  Malluche and others (1984)
first claimed osteocalcin as a useful marker re-
flecting the state of bone formation by demon-
strating that there was a significant correlation
between osteocalcin and cellular and noncellu-
lar parameters of bone formation including
bone turnover.  In general, i-PTH values below
60–65 pg/mL reflect adynamic bone disease,
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while those above 450–460 pg/mL reflect osteitis
fibrosa.  Clearly, bone turnover markers are
thus useful as noninvasive diagnostic markers
of renal osteodystrophy.  However, bone biopsy
is necessary when i-PTH values between 65 and
460 pg/mL reflect various histologic features of
renal osteodystrophy as reported by Faugere
and others (1994).
Conclusion
Possible correlations between VDR polymor-
phic genotypes and factors involving BMD
were  evaluated in 209 patients with chronic re-
nal failure by assessing allele and genotype
frequencies of VDR polymorphisms, bone turn-
over markers and BMD.  Individuals having B,
A, t and f haplotypes showed low levels of
serum osteocalcin and i-PTH and low BMD.
The histologic spectrum of bone diseases as
assessed by biopsy did not significantly vary
depending on different restriction endonu-
cleases used for VDR genotyping.  VDR poly-
morphism was shown to be one of the factors
determining BMD.  Histologic features of bone
in renal osteodystrophpy failed to correlate with
VDR polymorphisms, probably due to bias
generated by clinical improvement due to medi-
cation.  Further studies that exclude the distort-
ing effects of active vitamin D and calcium sup-
plementations are warranted to clarify this mat-
ter.
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